Condition
NRAS Mutation clinical trials and research
As of November 12, 2026, Find a Trial lists 2 NRAS Mutation clinical trials that are recruiting, at sites in 2 countries (most in China (1), United States (1)). By phase: Phase 2 (1), Phase 1/2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 2Countries
All recruiting trials (2)
-
Combo of tunlametinib, pucotenlimab, and hydroxychloroquine in NRAS-mutant melanoma
This study tests whether adding hydroxychloroquine to tunlametinib and pucotenlimab helps people with NRAS-mutant melanoma.
-
First-in-human use of RLY-8161 in advanced NRAS-mutant solid tumors
This Phase 1 trial will test whether RLY-8161, a drug that selectively targets NRAS mutations, is safe and shows anti-tumor activity in people with advanced NRAS-mutant melanoma or other NRAS-mutant solid tumors.
Related topics
Quick answers
How many NRAS Mutation clinical trials are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in China (1 trial), United States (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.